Gabriela Hobbs, MD

Gabriela Hobbs, MD

Clinical Director of Leukemia ServiceMass General

Dr. Gabriela Hobbs's primary clinical and research focus is in advancing the care of patients with myeloproliferative neoplasms (MPN). Her primary clinical objective is to continue to develop a panel of patients with MPN from local and regional referrals. The goal of her research is to design and implement clinical trials for patients with MPNs with a significant translational component through collaborations with laboratory investigators.

Related

Doctor talking to patient
Myeloproliferative Neoplasms

New Myelofibrosis Approvals: Better Survival?

Gabriela Hobbs, MD, Mass General, discusses new approvals for myelofibrosis, who will respond to which treatment, and what all of this means for prognosis.

Doctor talking to patient
Myeloproliferative Neoplasms

New Myelofibrosis Approvals: Better Survival?

Gabriela Hobbs, MD, Mass General, discusses new approvals for myelofibrosis, who will respond to which treatment, and what all of this means for prognosis.

Senior taking medication
Myeloproliferative Neoplasms

Treatment Options for PV Besides Hydroxyurea

Gabriela Hobbs, MD, Mass General, discusses the right treatment for your polycythemia vera (PV) and whether patients with PV should be on a statin.

Senior taking medication
Myeloproliferative Neoplasms

Treatment Options for PV Besides Hydroxyurea

Gabriela Hobbs, MD, Mass General, discusses the right treatment for your polycythemia vera (PV) and whether patients with PV should be on a statin.

Senior getting an injection
Myeloproliferative Neoplasms

Are New Treatments Coming for ET?

Gabriela Hobbs, MD, Mass General, discusses new treatments for JAK2 mutation positive ET and the vaccine approach being studied for the CALR mutation.

Senior getting an injection
Myeloproliferative Neoplasms

Are New Treatments Coming for ET?

Gabriela Hobbs, MD, Mass General, discusses new treatments for JAK2 mutation positive ET and the vaccine approach being studied for the CALR mutation.

Senior woman hiking
Myeloproliferative Neoplasms

Is MPN a Leukemia?

While there is a connection between MPNs and leukemia, it is not something that should scare MPN patients. Learn more.

Senior woman hiking
Myeloproliferative Neoplasms

Is MPN a Leukemia?

While there is a connection between MPNs and leukemia, it is not something that should scare MPN patients. Learn more.

IV drip
Myeloproliferative Neoplasms

Bone Marrow Biopsy Pain, Frequency and Possible Alternatives

The pain of bone marrow biopsies has seemingly been forgotten as the procedure is still commonly done in office as supposed to out of office with sedation.

IV drip
Myeloproliferative Neoplasms

Bone Marrow Biopsy Pain, Frequency and Possible Alternatives

The pain of bone marrow biopsies has seemingly been forgotten as the procedure is still commonly done in office as supposed to out of office with sedation.

Conference Interview
Myeloproliferative Neoplasms

2022 ASH Conference Report: Myelofibrosis Updates

Watch as an expert updates our myelofibrosis patient community on the newest research presented at the 2022 ASH Annual Meeting.

Conference Interview
Myeloproliferative Neoplasms

2022 ASH Conference Report: Myelofibrosis Updates

Watch as an expert updates our myelofibrosis patient community on the newest research presented at the 2022 ASH Annual Meeting.

MPN Progression and Polycythemia Vera
Myeloproliferative Neoplasms

MPN Progression and Polycythemia Vera

What have we learned about MPN progression, particularly in polycythemia vera? Hear a doctor explain.

MPN Progression and Polycythemia Vera
Myeloproliferative Neoplasms

MPN Progression and Polycythemia Vera

What have we learned about MPN progression, particularly in polycythemia vera? Hear a doctor explain.

ASH 2021: Essential Thrombocythemia Treatment Updates
Myeloproliferative Neoplasms

ASH 2021: Essential Thrombocythemia Treatment Updates

An MPN specialist shares the latest updates on essential thrombocythemia from the 2021 American Society of Hematology (ASH) conference.

ASH 2021: Essential Thrombocythemia Treatment Updates
Myeloproliferative Neoplasms

ASH 2021: Essential Thrombocythemia Treatment Updates

An MPN specialist shares the latest updates on essential thrombocythemia from the 2021 American Society of Hematology (ASH) conference.

Disease Progression in Myeloproliferative Neoplasms
Myeloproliferative Neoplasms

Disease Progression in Myeloproliferative Neoplasms

A patient advocate and myeloproliferative neoplasm (MPN) expert discuss everything you need to know about disease progression.

Disease Progression in Myeloproliferative Neoplasms
Myeloproliferative Neoplasms

Disease Progression in Myeloproliferative Neoplasms

A patient advocate and myeloproliferative neoplasm (MPN) expert discuss everything you need to know about disease progression.

New Clinical Trials for MPNs in 2021 and Beyond
Myeloproliferative Neoplasms

New Clinical Trials for MPNs in 2021 and Beyond

Myeloproliferative neoplasm (MPN) experts answer common questions on clinical trials during the time of COVID-19.

New Clinical Trials for MPNs in 2021 and Beyond
Myeloproliferative Neoplasms

New Clinical Trials for MPNs in 2021 and Beyond

Myeloproliferative neoplasm (MPN) experts answer common questions on clinical trials during the time of COVID-19.

Watchful Waiting and Decision-Making with MPNs
Myeloproliferative Neoplasms

Watchful Waiting and Decision-Making with MPNs

Doctor shares advice on the watch and wait period for MPNs and offers insight into the decision-making process for treatment.

Watchful Waiting and Decision-Making with MPNs
Myeloproliferative Neoplasms

Watchful Waiting and Decision-Making with MPNs

Doctor shares advice on the watch and wait period for MPNs and offers insight into the decision-making process for treatment.